- NLM Classification (23)
- QU Biochemistry (19)
- QU 300-375 Cells (19)
- QU Biochemistry (19)
Eder, C. and Wild, C. (2019): Advanced Therapy Medicinal Products (ATMPs): Technology forecast. Journal of Market Access & Health Policy 7 (1).
Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.
Geiger-Gritsch, S. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: CAR-T Cell Therapy. AIHTA Policy Brief 006a.
Hofer, V. and Goetz, G. (2023): Allogeneic mesenchymal stem cells for Crohn's Disease-associated complex perianal fistulas. 1st Update 2023. Decision Support Document 111/ Update 2023.
Jeindl, R. and Mayer-Ferbas, J. (2024): CAR-based immunotherapy with a focus on CAR-NK cells. Rapid Review Nr.: 013.
Langer, T. (2006): [Stem cell transplantation for acute leukemia]. HTA-Newsletter 52: pp. 2-3.
Panhuber, A. and Titieni-Schuhmann, A. and Goetz, G. and Wild, C. (2022): CAR-T cell therapy: Contrasting the evidence from pivotal trials with the real world evidence (RWE). HTA-Projektbericht 146.
Pramesberger, C. and Adlbrecht, C. and Guba, B. and Felder-Puig, R. (2008): [New minimally invasive methods in the treatment of stress urinary incontinence. Systematic review]. Decision Support Document 06.
Riegelnegg, M. and Jeindl, R. (2023): Autologous fat grafting in osteoarthritis. Rapid Review Nr.: 007.
Rothschedl, E. and Grössmann, N. (2023): Avapritinib (Ayvakyt®) for the treatment of indolent systemic mastocytosis (ISM). Fact Sheet Nr. 157.
Sehic, O. and Wild, C. (2022): ATMPs and Gene Therapies in Development. Horizon Scanning – Update 2022. AIHTA Policy Brief 006b/ 1. Update.
Sehic, O. and Wild, C. (2022): CAR-T Cell-Therapies in Development, Update 2022. AIHTA Policy Brief 006a/ 1. Update.
Wild, C. and Wohlhöfner, K. and Sehic, O. and Grössmann, N. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: ATMPs and Gene Therapies. AIHTA Policy Brief 006b.
Wild, C. (2003): [High-dose chemotherapy]. HTA-Newsletter 22: p. 4.
Wild, C. (2001): [Stem cell research, quo vadis? Editorial]. HTA-Newsletter 03: pp. 1-2.
Wild, C. (2001): [Stem cells: Quo vadis?]. ITA-Newsletter September 2001: pp. 8-9.
Wild, C. (2001): [Stem cell research, quo vadis?]. ORF ON Science.
Wild, C. and Grössmann, N. (2019): FoundationOne®CDx: genetic profiling of solid tumours. Rapid Assessment 014.
Wolf, S. and Stanak, M. (2018): Allogeneic mesenchymal stem cells for Crohn’s disease-associated complex perianal fistulas. Decision Support Document 111.